» Articles » PMID: 17177202

Chronic Haloperidol Treatment Results in a Decrease in the Expression of Myelin/oligodendrocyte-related Genes in the Mouse Brain

Overview
Journal J Neurosci Res
Specialty Neurology
Date 2006 Dec 21
PMID 17177202
Citations 27
Authors
Affiliations
Soon will be listed here.
Abstract

Schizophrenia is a complex psychiatric illness that manifests as a combination of positive symptoms, negative symptoms, and cognitive deficits. Antipsychotic drugs, such as haloperidol, attenuate dopamine receptor signaling in neurons and constitute the frontline treatment for the positive symptoms of schizophrenia. However, haloperidol treatment has also been reported to exacerbate preexisting negative symptoms/cognitive deficits and the severity of these deficits has been correlated with white matter pathology in schizophrenia. Indeed, several studies implicate oligodendrocyte function in the pathophysiology of schizophrenia, but it is unknown whether these effects are related to drug treatment. It is well established that haloperidol alters gene expression in neurons. However, its effect on oligodendrocytes is unknown. In this study, we investigate the effects of chronic haloperidol treatment on the expression of eight genes known to play critical roles in myelin/oligodendrocyte function. We treated male mice with haloperidol (2 mg/kg/day) for 30 days and measured gene expression changes by using in situ hybridization analysis and quantitative densitometry. Haloperidol caused a decrease in the expression of these genes in several white matter regions of the mouse CNS. In contrast, clozapine (10 mg/kg/day) had no effect on the expression of a subset of these genes. This has important implications for both disease pathology and the consideration of treatment options for patients.

Citing Articles

The Lack of Dopamine Transporter Is Associated With Conditional Associative Learning Impairments and Striatal Proteomic Changes.

Savchenko A, Muller C, Lubec J, Leo D, Korz V, Afjehi-Sadat L Front Psychiatry. 2022; 13:799433.

PMID: 35370807 PMC: 8971526. DOI: 10.3389/fpsyt.2022.799433.


Multi-Scale Understanding of NMDA Receptor Function in Schizophrenia.

Hyun J, Inoue T, Hayashi-Takagi A Biomolecules. 2020; 10(8).

PMID: 32796766 PMC: 7465114. DOI: 10.3390/biom10081172.


Synaptic functions and their disruption in schizophrenia: From clinical evidence to synaptic optogenetics in an animal model.

Obi-Nagata K, Temma Y, Hayashi-Takagi A Proc Jpn Acad Ser B Phys Biol Sci. 2019; 95(5):179-197.

PMID: 31080187 PMC: 6742729. DOI: 10.2183/pjab.95.014.


Increased and Decreased Superficial White Matter Structural Connectivity in Schizophrenia and Bipolar Disorder.

Ji E, Guevara P, Guevara M, Grigis A, Labra N, Sarrazin S Schizophr Bull. 2019; 45(6):1367-1378.

PMID: 30953566 PMC: 6811818. DOI: 10.1093/schbul/sbz015.


Gene expression over the course of schizophrenia: from clinical high-risk for psychosis to chronic stages.

Ota V, Moretti P, Santoro M, Talarico F, Spindola L, Xavier G NPJ Schizophr. 2019; 5(1):5.

PMID: 30923314 PMC: 6438978. DOI: 10.1038/s41537-019-0073-0.